Abstract: The invention provides derivatives and analogs of triazatetracyclo[7.7.0.01,13.02,7]-hexadeca-2,4,6,10,12-pentaenes, 5,7,11-triazatetracyclo[8.7.0.01,6.012,17]-heptadeca-6,8,12,14,16-pentaenes, pharmaceutical compositions comprising these compounds and methods for treatment of hepatitis C viral infections using these compounds.

Abstract: The invention provides derivatives and analogues of triazatetracyclo[7.7.0.01,13,02,7]-hexadeca-2,4,6,10,12-pentaenes, 5,7,11-triazatetracyclo[8.7.0.01,6,012,17]-heptadeca-6,8,12,14,16-pentaenes, pharmaceutical compositions comprising these compounds and methods for treatment of hepatitis C viral infections using these compounds.

Abstract: The present invention describes a method for producing membrane receptors based on a baculovirus/insect cell system. The invention further includes the receptors produced by the method described herein, a model for studying the properties of these membrane receptors and an assay to screen molecules that are active on these membrane receptors.

Abstract: An isolated and substantially pure mammal polypeptide different from known adrenergic, serotonine and dopamine receptors, existing at least on mammalian muscle and eosinophils membranes, for instance in rat, guinea pig and humans. The invention also relates to plasmids containing the genes coding for said polypeptide, to host cells transformed by genes coding for the above mentioned polypeptide, to nucleotide probes capable of hybridizing with the genes coding for the above mentioned polypeptide, and to polyclonal and monoclonal antibodies directed against the above mentioned polypeptide.

Abstract: Method of producing a recombinant membrane receptor protein by introducing a baculovirus expression vector encoding the membrane receptor protein into a host cell, culturing the resultant host cell for a sufficient time to permit expression of the membrane receptor protein and baculovirus viral particles and separating the cells from the viral particles. The baculovirus viral particles are then recovered.

Abstract: The invention concerns aryloxypropanolamine derivatives having at least an anti-diabetic and anti-fat activity and their methods of preparation and applications, particularly as human and veterinary medicine and animal food additive.

Abstract: The invention concerns nucleic sequences coding for a protein capable of interacting with the AT2 receptor, oligonucleotides included in said sequences, their applications as probes and for expressing said proteins, vectors useful for said expression, host cells containing said vectors, and study model of AT2 receptor. The invention also concerns said proteins and their uses. Said isolated nucleic acid fragment coding for a protein capable of binding with the AT2 receptor is selected among the group consisting of the sequences SEQ ID NO: 1, 3, 5, 7 and 9.

Abstract: The present invention relates to a method for producing membrane receptors based on a baculovirus/insect cell system. The invention further includes the receptors produced by the method described herein, a model for studying the properties of these membrane receptors and an assay to screen molecules that are active on these membrane receptors.

Abstract: Method for producing membrane receptors based on a baculovirus/insect cell system. The invention further includes the receptors produced by the method described herein, a model for studying the properties of these membrane receptors and an assay to screen molecules that are active on these membrane receptors.

Abstract: The invention relates to optionally modified immortalized lines of endothelial brain cells of mammalians, as well as applications as preventive or curative drug and particularly for the treatment of primary and secondary, neurologic or psychiatric diseases, including brain tumor, and for stimulating the growth and reproduction of breeding animals. The invention also relates to the method for preparing said cell lines.

Abstract: The invention concerns aryloxypropanolamine derivatives having at least an anti-diabetic and anti-fat activity and their methods of preparation and applications, particularly as human and veterinary medicine and animal food additive. These derivatives comply with the general formula (I) in which R2 represents one of the following groups: —CH2—, —CH2—CH2, —CH(CH3)—CH2—, —C(CH3)═CH—, —C(CH3)2—CH2— or a bond; Q represents: (i) a phenyl radical 3,4-disubstituted alkylene dioxy determining with the phenyl radical, a non-substituted benzodioxane unit, a non-substituted benzodioxol unit, or a 2-substituted benzodioxol unit, (ii) a phenyl radical 3 and/or 4-substituted, by a O—(CH2)x—COOR5 group, (iii) a condensed polycyclic hydrocarbon comprising at least two condensed cycles, (iv) a cyclic hydrocarbon system, optionally cross-linked, and constituting a cycloalkane comprising 1, 2 or 3 cycles.

Abstract: Immortalized cell lines from human adipose tissue, process for preparing same and applications thereof as a study model for the physiopathology of the metabolism and particularly for obesity and diabetes, as tools for developing drugs for the treatment of disease states linked to metabolic disorders such as obesity and diabetes, and as drugs. The cell lines are formed of pre-adipocytes containing a nucleic acid fragment including at least one fragment immortalizing a viral oncogene, and at least one promoter selected from the group containing a promoter of said viral oncogene and a human vimentine gene regulatory region fragment. They express at least one of the following proteins: the .beta.1 and .beta.2-adrenergic receptors, the uncoupling protein (UCP), the glucose transporters, Glut1 and Glut 4 and lipoprotein lipase (LPL). They are capable of being converted into mature adipocytes which product fat and further express the .alpha.2.sub.A and .beta.

Abstract: Nucleotide sequences encoding the murine .beta.3-adrenergic receptor are provided. Use of the sequences as probes, in vectors, and for the expression of peptides are discussed. Methods of screening substances for agonist or antagonist action towards .beta.3-adrenergic receptors, and for detecting the affinity of various substances for .beta.3-adrenergic receptors, are described.

Abstract: Specific peptide fragment from the feline immunodeficiency virus (FIV), and its use as a diagnostic reagent.The said peptide fragment, derived from the Env protein of the Wo strain of the feline immunodeficiency virus (FIV) (peptide P253), corresponds to positions 693-709 of the said Env protein and exhibits the following sequence:Leu-Gly-X-Asn-Gln-Asn-Gln-Phe-Phe-X-Lys-Val-Pro-Ser-Ala-, in which X represents a cysteine or a serine, as follows:Leu-Gly-Cys-Asn-Gln-Asn-Gln-Phe-Phe-Cys-Lys-Val-Pro-Ser-Ala (SEQ ID NO: 1),Leu-Gly-Ser-Asn-Gln-Asn-Gln-Phe-Phe-Ser-Lys-Val-Pro-Ser-Ala (SEQ ID NO: 2),Leu-Gly-Cys-Asn-Gln-Asn-Gln-Phe-Phe-Ser-Lys-Val-Pro-Ser-Ala (SEQ ID NO: 3),Leu-Gly-Ser-Asn-Gln-Asn-Gln-Phe-Phe-Cys-Lys-Val-Pro-Ser-Ala (SEQ ID NO: 4).